Conservative Massachusetts Think Tank Slams State’s 340B Hospitals over Charity Care and Calls for Reform

title page of Pioneer Institute white paper on 340B drug discounts
Charity care at five Massachusetts hospital groups declined at a time that 340B sales to the hospitals were rising, a new report by a conservative state think tank says. The state hospital association says the report distorts the 340B program.

Charity care has been declining significantly in some Massachusetts hospital systems, raising “a significant policy issue for the 340B program,” a free-market-oriented Massachusetts think tank whose donors include pharmaceutical manufacturers says in a new report.

The state hospital

Read More »

News Alert

HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy

Boehringer Ingelheim exterior sign and building
HRSA has referred Boehringer Ingelheim to the HHS Inspector General for possible imposition of civil monetary penalties over BI's conditions on 340B pricing when hospitals use contract pharmacies.

The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”

HRSA told BI in a

Read More »

HRSA Invokes Contract Pharmacy Fight in Pitch for Comprehensive 340B Regulatory Power

Department of Health and Human Service budget title page
HRSA yesterday told Congress in its budget request that it needed comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program.

Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it

Read More »

Arkansas Health Centers and Community Hospital Want Role in Challenging PhRMA’s Lawsuit Over State’s Novel 340B Contract Pharmacy Law

Entrance to Mid Delta Health Center
Mid Delta Health Center is a member of Community Health Centers of Arkansas, which wants to intervene in PhRMA's lawsuit challenging the state's one-of-a-kind law protecting 340B contract pharmacy arrangements.

Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.

Community Health Centers of Arkansas (CHCA) filed the motion yesterday

Read More »

Feds Take Over Prosecution of Whistleblower Suit Against Tenn. Health System Alleged to Have Paid Cancer Docs Illegally for Referrals that Boosted 340B Profits

Methodist University hospital building
The federal government has decided to intervene in a 340B-related whistleblower lawsuit involving Methodist University Hospital in Memphis, Tenn.

The federal government has decided to intervene in a whistleblower lawsuit that accuses a Tennessee health system of paying Memphis-area cancer physicians for referrals that allegedly generated about $70 million a year in profits for the health system from

Read More »

HIV/AIDS Advocates Protest in Front of Gilead HQ Against Company’s New 340B Contract Pharmacy Policy

advocates march with Stop Being Greedy signs
AHF held a demonstration in front of Gilead's headquarters protesting the company’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

UPDATE Thursday, March 24, 2022, 2:10 p.m.A Gilead spokesperson disputed AIDS Healthcare Foundation’s statement that, under Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments, the company will give 340B discounts to covered entities

Read More »

BMS Providing 340B Refunds on Cancer Drug Opdivo

Bristol Myers Squibb outdoor sign
BMS is providing credits for 340B overcharges during Q3 2021 on one new NDC of its cancer drug Opdivo.

Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.

BMS posted the refund notice on the U.S. Health Resources and

Read More »

Could J&J’s Decision to Limit 340B Contract Pharmacy Spur Congress to Act?

Johnson & Johnson exterior building sign
Could Johnson & Johnson's conditions on 340B drug sales to hospitals involving contract pharmacy be the thunderclap that rouses Congress?

Yesterday, we broke the news that Johnson & Johnson announced conditions on 340B drug sales to hospitals on a host of pharmacy inventory staples including immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders,

Read More »

Influential Group that Offers Conservative Model Bills to State Lawmakers Wades into 340B Debate

ALEC wordmark
Requiring drug manufacturers “to sell to contract pharmacies at the 340B discount is price-fixing,” the American Legislative Exchange Council says.

Requiring drug manufacturers “to sell to contract pharmacies at the 340B discount is price-fixing,” an influential source of model bills for conservative state lawmakers says in a new post on its website.

“Legislators understandably worry about the cost

Read More »

Nebraska Governor Signs 340B Anti-Discrimination Bill

Gov. Pete Ricketts signing legislation
Nebraska Gov. Pete Ricketts (R) signed legislation to protect 340B covered entities and their contract pharmacies from discrimination by PBMs.

Nebraska Gov. Pete Ricketts (R) signed legislation last week to protect 340B covered entities and their contract pharmacies from discrimination by pharmacy benefit managers.

Legislative Bill 767 makes Nebraska the third known state to take such action

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live